BCL2 and acute lymphoblastic leukemia: Venetoclax, a BCL-2 inhibitor, has been gaining interest in the treatment armamentarium of ALL given multiple studies demonstrating efficacy across the phenotypic spectrum, including T-cell and early T-cell progenitor (ETP) ALL, often showing resistance to the first 7 days of GC treatment [46–48, 92–98].